/Company Directory

/

Asset Brief

SNT-5505 (amsulostat)

SNT·Syntara·High-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML) in combination with azacitidine·Phase 1/2·[ TODO: fill in ]

Plain-language Brief

The trial in plain terms

The disease: Myelodysplastic syndromes (MDS) are a group of blood cancers in which the bone marrow does not produce enough healthy blood cells. High-risk MDS carries a substantial risk of progression to acute myeloid leukaemia (AML) and is associated with poor survival. Chronic myelomonocytic leukaemia (CMML) is a related blood cancer that shares features of both MDS and a separate category called myeloproliferative neoplasms. Both conditions represent a significant unmet medical need, particularly in patients who do not respond adequately to available treatments.
What the asset is trying to do: SNT-5505 (amsulostat) is classified as a kinase inhibitor, meaning it works by blocking the activity of one or more enzymes called kinases that play a role in cell growth or survival. The AZALOX study is evaluating amsulostat in combination with azacitidine, a standard hypomethylating agent (a drug that alters gene expression) already used in MDS and CMML. The specific molecular target of amsulostat is not disclosed in the available data.
What the trial is measuring, and why it matters: The AZALOX study is assessing the combination of amsulostat with azacitidine in patients with high-risk MDS or CMML. Based on the study name and phase designation, the trial is expected to evaluate safety and tolerability in the Phase 1 portion and preliminary efficacy in the Phase 2 portion, though the specific registered endpoints are not available in the provided data.
Efficacy benchmarks in this setting: In high-risk MDS, the hypomethylating agent azacitidine has been shown to achieve an overall response rate (ORR, including complete and partial responses) of approximately 29% and a median overall survival of approximately 24 months versus approximately 15 months for conventional care, based on the pivotal AZA-001 trial (Fenaux et al, Lancet Oncology 2009). In CMML, azacitidine has demonstrated response rates in a similar range in published studies, though patient selection varies across trials. Early-stage data from the AZALOX study, when reported, will not be statistically comparable to these figures given differences in patient numbers, selection criteria, and study design.
Commercial context

Trial Design

Design summary

Phase: Phase 1/2
Design type: [ TODO: fill in ] — phase 1/2 combination study (AZALOX). Likely open-label based on phase and setting; confirm from trial registry.
Primary endpoint: [ TODO: fill in ]
Key secondary endpoints: [ TODO: fill in ]
Enrolment target: [ TODO: fill in ]
Current enrolment status: [ TODO: fill in ]
Sites: [ TODO: fill in ]
Expected readout window: Interim safety and efficacy data described as expected mid-2026 (per Syntara AZALOX study notes provided). A trial registry entry with formal primary completion date is not available in the provided data.

Asset Track Record

Did SNT deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

5 July 2026data readoutEncouraging SNT-4728 Phase 2 iRBD resultshit · positivesrc ASX ↗
30 June 2026regulatory decisionEMA Orphan Drug Designation decision (MF)overdue
30 June 2026regulatory decisionFDA feedback on myelofibrosis development planoverdueASX ↗
30 June 2026data readoutPhase 2 MF combo (ruxolitinib) efficacy data readoutoverdueASX ↗
10 June 2026financingResults of Share Purchase Planhitsrc ASX ↗
14 May 2026financingUpdate - Proposed issue of securities - SNThitsrc ASX ↗
13 May 2026financingShare Purchase Plan Offer Booklethitsrc ASX ↗
28 Apr 2026regulatory decisionAmsulostat (SNT-5505) FDA — Positive FDA feedback for Amsulostat P2b trialhit · positivesrc ASX ↗

Class Catalyst Calendar

What's landed, what's next for SNT-5505 (amsulostat) and peers

SNT-5505 (amsulostat)'s own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for SNT-5505 (amsulostat). Showing past 6 months and next 12 months · 10 later hidden.

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Trial design comparison

How SNT-5505 (amsulostat) reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
SNT-5505 (amsulostat)	Syntara	Kinase Inhibitor	Phase 1/2[ TODO: fill in ]	[ TODO: fill in ] — phase 1/2 combination study (AZALOX). Likely open-label based on phase and setting; confirm from trial registry.	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	0
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

Kinase InhibitorASX peers ›

7 activeexpand ›

PU
AZA+Lus VS AZA Monotherapy in HR-MDS
Phase 3
Peking Union Medical College Hospital·Not yet recruiting·Primary completion 31 Jan 2026·NCT06927232
SH
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

Curated Commentary

Third-party coverage(none curated yet)

expand ›

External analyst notes, journalism, and industry commentary cited with attribution.

No third-party coverage curated for SNT-5505 (amsulostat) yet. Broker coverage of Syntara is thin; named analyst notes will appear here as they become available. For now, see the company's ASX announcements and the linked sponsor / class sources elsewhere on this page.

Asset Track Record

Did SNT deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

5 July 2026data readoutEncouraging SNT-4728 Phase 2 iRBD resultshit · positivesrc ASX ↗
30 June 2026regulatory decisionEMA Orphan Drug Designation decision (MF)overdue
30 June 2026regulatory decisionFDA feedback on myelofibrosis development planoverdueASX ↗
30 June 2026data readoutPhase 2 MF combo (ruxolitinib) efficacy data readoutoverdueASX ↗
10 June 2026financingResults of Share Purchase Planhitsrc ASX ↗
14 May 2026financingUpdate - Proposed issue of securities - SNThitsrc ASX ↗
13 May 2026financingShare Purchase Plan Offer Booklethitsrc ASX ↗
28 Apr 2026regulatory decisionAmsulostat (SNT-5505) FDA — Positive FDA feedback for Amsulostat P2b trialhit · positivesrc ASX ↗

Class Catalyst Calendar

What's landed, what's next for SNT-5505 (amsulostat) and peers

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Trial design comparison

How SNT-5505 (amsulostat) reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
SNT-5505 (amsulostat)	Syntara	Kinase Inhibitor	Phase 1/2[ TODO: fill in ]	[ TODO: fill in ] — phase 1/2 combination study (AZALOX). Likely open-label based on phase and setting; confirm from trial registry.	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	0
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

Kinase InhibitorASX peers ›

7 activeexpand ›

PU
AZA+Lus VS AZA Monotherapy in HR-MDS
Phase 3
Peking Union Medical College Hospital·Not yet recruiting·Primary completion 31 Jan 2026·NCT06927232
SH
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

SNT-5505 (amsulostat)n = 0

Syntara·Kinase Inhibitor·Phase 1/2·[ TODO: fill in ]

Design: [ TODO: fill in ] — phase 1/2 combination study (AZALOX). Likely open-label based on phase and setting; confirm from trial registry.
Primary endpoint: [ TODO: fill in ]
Dosing: [ TODO: fill in ]
Eligibility: [ TODO: fill in ]

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemian = —

Otsuka Australia Pharmaceutical Pty Ltd·Small Molecule Other·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

AZA+Lus VS AZA Monotherapy in HR-MDSn = —

Peking Union Medical College Hospital·Kinase Inhibitor·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)n = —

Gruppo Italiano Malattie EMatologiche dell'Adulto·Allogeneic Cell Therapy Other·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndromen = —

AbbVie·Small Molecule Other·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).n = —

Ascentage Pharma Group Inc.·Other·Phase 3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCTn = —

University of Birmingham·Other·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSn = —

M.D. Anderson Cancer Center·Small Molecule Other·PHASE2/PHASE3

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemian = —

National Cancer Institute (NCI)·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemian = —

City of Hope Medical Center·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancyn = —

Masonic Cancer Center, University of Minnesota·Allogeneic Cell Therapy Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patientsn = —

Stichting Hemato-Oncologie voor Volwassenen Nederland·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPNn = —

The First Affiliated Hospital with Nanjing Medical University·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDSn = —

University of Virginia·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapyn = —

GCP-Service International West GmbH·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDSn = —

First Affiliated Hospital of Zhejiang University·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patientsn = —

Institute of Hematology & Blood Diseases Hospital, China·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromesn = —

Akeso·Monoclonal antibody·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AMLn = —

Ryvu Therapeutics SA·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDSn = —

First Affiliated Hospital of Zhejiang University·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromen = —

M.D. Anderson Cancer Center·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDSn = —

Beijing 302 Hospital·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplantn = —

M.D. Anderson Cancer Center·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donorn = —

St. Petersburg State Pavlov Medical University·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemian = —

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndromen = —

M.D. Anderson Cancer Center·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)n = —

National Cancer Institute (NCI)·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)n = —

National Cancer Institute (NCI)·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

HCT With PTCy in Higher-risk MDSn = —

Asan Medical Center·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasian = —

Ciusss de L'Est de l'Île de Montréal·Allogeneic Cell Therapy Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantationn = —

University Hospital Tuebingen·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasmn = —

M.D. Anderson Cancer Center·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratificationn = —

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromen = —

M.D. Anderson Cancer Center·Antibody-drug conjugate·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignanciesn = —

Masonic Cancer Center, University of Minnesota·Allogeneic Cell Therapy Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blastsn = —

M.D. Anderson Cancer Center·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)n = —

M.D. Anderson Cancer Center·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patientsn = —

Institute of Hematology & Blood Diseases Hospital, China·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Ascorbate in Myelodysplastic Syndromen = —

Prajwal Dhakal·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.n = —

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla·Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromen = —

M.D. Anderson Cancer Center·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)n = —

BioLite, Inc.·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromesn = —

Yehui Tan·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)n = —

University of Illinois at Chicago·Surgical Device·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)n = —

National Cancer Institute (NCI)·Kinase Inhibitor·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemian = —

M.D. Anderson Cancer Center·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDSn = —

Beijing 302 Hospital·Small Molecule Other·Phase 2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndromen = —

Akeso·Monoclonal antibody·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Omacetaxine + Azacitidine in Untreated Patients With High Grade MDSn = —

University of Colorado, Denver·Small Molecule Other·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromesn = —

Groupe Francophone des Myelodysplasies·Small Molecule Other·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemian = —

M.D. Anderson Cancer Center·Small Molecule Other·PHASE1/PHASE2

Design: —
Primary endpoint: —
Dosing: —
Eligibility: —

Small Molecule OtherASX peers ›

24 activeexpand ›

OA
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Phase 3
Otsuka Australia Pharmaceutical Pty Ltd·Active, not recruiting·Primary completion 6 Dec 2024·NCT05883956
A
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
Phase 3
AbbVie·Active, not recruiting·Primary completion 1 July 2027·NCT04401748
MA
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
PHASE2/PHASE3
M.D. Anderson Cancer Center·Recruiting·Primary completion 31 Dec 2027·NCT04708054
NC
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Phase 2
National Cancer Institute (NCI)·Active, not recruiting·Primary completion 1 June 2015·NCT01522976
CO
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Phase 2
City of Hope Medical Center·Active, not recruiting·Primary completion 27 Dec 2019·NCT01885689
GI
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
Phase 2
GCP-Service International West GmbH·Active, not recruiting·Primary completion 30 Sept 2025·NCT05583552
FA
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
Phase 2
First Affiliated Hospital of Zhejiang University·Recruiting·Primary completion 19 Oct 2025·NCT06046313
IO
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Phase 2
Institute of Hematology & Blood Diseases Hospital, China·Not yet recruiting·Primary completion 30 Oct 2025·NCT06900088
FA
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
Phase 2
First Affiliated Hospital of Zhejiang University·Not yet recruiting·Primary completion 2 Apr 2026·NCT06050941
MA
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2
M.D. Anderson Cancer Center·Recruiting·Primary completion 1 June 2026·NCT04493164
SP
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
Phase 2
St. Petersburg State Pavlov Medical University·Recruiting·Primary completion 10 Dec 2026·NCT07238712
MA
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2
M.D. Anderson Cancer Center·Recruiting·Primary completion 28 Feb 2027·NCT03383575
UH
Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation
Phase 2
University Hospital Tuebingen·Not yet recruiting·Primary completion 1 Aug 2027·NCT07214064
MA
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
Phase 2
M.D. Anderson Cancer Center·Recruiting·Primary completion 31 Dec 2027·NCT05365035
MA
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Phase 2
M.D. Anderson Cancer Center·Recruiting·Primary completion 1 Feb 2028·NCT01515527
PD
Ascorbate in Myelodysplastic Syndrome
Phase 2
Prajwal Dhakal·Recruiting·Primary completion 1 May 2028·NCT07283900
MA
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2
M.D. Anderson Cancer Center·Recruiting·Primary completion 11 Oct 2028·NCT00801489
BI
A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Phase 2
BioLite, Inc.·Not yet recruiting·Primary completion 31 Dec 2028·NCT02944955
YT
Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes
Phase 2
Yehui Tan·Recruiting·Primary completion 30 June 2029·NCT07047183
MA
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Phase 2
M.D. Anderson Cancer Center·Recruiting·Primary completion 31 May 2030·NCT02115295
B3
Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
Phase 2
Beijing 302 Hospital·Recruiting·Primary completion 1 June 2030·NCT07238686
UO
Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS
PHASE1/PHASE2
University of Colorado, Denver·Active, not recruiting·Primary completion 7 Oct 2025·NCT03564873
GF
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
PHASE1/PHASE2
Groupe Francophone des Myelodysplasies·Active, not recruiting·Primary completion 1 Dec 2025·NCT05782127
MA
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
PHASE1/PHASE2
M.D. Anderson Cancer Center·Active, not recruiting·Primary completion 31 Mar 2026·NCT04550442

OtherASX peers ›

11 activeexpand ›

AP
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Phase 3
Ascentage Pharma Group Inc.·Recruiting·Primary completion 1 June 2029·NCT06641414
UO
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
PHASE2/PHASE3
University of Birmingham·Active, not recruiting·Primary completion 1 May 2026·NCT04217278
UO
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
Phase 2
University of Virginia·Active, not recruiting·Primary completion 9 May 2025·NCT04482894
B3
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Phase 2
Beijing 302 Hospital·Recruiting·Primary completion 31 July 2026·NCT06536959
MA
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
Phase 2
M.D. Anderson Cancer Center·Active, not recruiting·Primary completion 31 Aug 2026·NCT02861417
FP
TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 2
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla·Not yet recruiting·Primary completion 30 Dec 2026·NCT06598969
NC
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Phase 2
National Cancer Institute (NCI)·Recruiting·Primary completion 31 Mar 2027·NCT05554406
AC
HCT With PTCy in Higher-risk MDS
Phase 2
Asan Medical Center·Active, not recruiting·Primary completion 31 May 2027·NCT06098313
SG
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification
Phase 2
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Recruiting·Primary completion 12 Nov 2027·NCT06612944
IO
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
Phase 2
Institute of Hematology & Blood Diseases Hospital, China·Recruiting·Primary completion 1 Apr 2028·NCT06918834
FP
TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.
Phase 2
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla·Not yet recruiting·Primary completion 1 Oct 2028·NCT06602323